441 related articles for article (PubMed ID: 28717990)
21. Treating hyperphosphatemia - current and advancing drugs.
Ketteler M; Liangos O; Biggar PH
Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
[TBL] [Abstract][Full Text] [Related]
22. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
23. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Floege J
J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
[TBL] [Abstract][Full Text] [Related]
24. The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt with: A Review of Current and Potential Phosphate Binders (PB).
Gosik R; Danel K
Mini Rev Med Chem; 2021; 21(19):3052-3061. PubMed ID: 34137362
[TBL] [Abstract][Full Text] [Related]
25. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
[TBL] [Abstract][Full Text] [Related]
26. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
27. Novel iron-based phosphate binders in patients with chronic kidney disease.
Shah HH; Hazzan AD; Fishbane S
Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
[TBL] [Abstract][Full Text] [Related]
28. Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Negri AL; Ureña Torres PA
Clin Kidney J; 2015 Apr; 8(2):161-7. PubMed ID: 25815172
[TBL] [Abstract][Full Text] [Related]
29. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
30. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
Locatelli F; Del Vecchio L; Violo L; Pontoriero G
Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
[TBL] [Abstract][Full Text] [Related]
31. Phosphate binders in chronic kidney disease: a systematic review of recent data.
Floege J
J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
[TBL] [Abstract][Full Text] [Related]
32. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
Nand N; Giri K; Jain D
J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.
Fathallah-Shaykh S; Drozdz D; Flynn J; Jenkins R; Wesseling-Perry K; Swartz SJ; Wong C; Accomando B; Cox GF; Warady BA
Pediatr Nephrol; 2018 Feb; 33(2):325-333. PubMed ID: 28900759
[TBL] [Abstract][Full Text] [Related]
34. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
[TBL] [Abstract][Full Text] [Related]
35. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
[TBL] [Abstract][Full Text] [Related]
36. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
37. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Cozzolino M; Brancaccio D
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
[TBL] [Abstract][Full Text] [Related]
39. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
Frazão JM; Adragão T
Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
[TBL] [Abstract][Full Text] [Related]
40. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
